Leqembi (lecanemab-irmb) - Biogen, Eisai
Kisunla (donanemab-azbt) - Eli Lilly
Baseline MRI markers and clinical outcomes during anti-amyloid β therapy: A real-world study in a Japanese dementia center. (PubMed, J Prev Alzheimers Dis) - Oct 19, 2026 - "Baseline medial temporal atrophy was associated with functional decline and microbleeds with ARIA-H. Pretreatment MRI may provide prognostic and safety information during anti-amyloid β therapy." 
Clinical data • Journal • Real-world evidence • CNS Disorders • Dementia
http://www.ncbi.nlm.nih.gov/pubmed/42892274
 
Aya Nakano; Daisuke Ito; Emi Qian; Eriko Ishihara; Hidenori Hattori; Hitoshi Katai; Ichiro Sugiyama; Kazuko Kamiyama; Kazunori Moritani; Manami Maruko; Marina Saito; Tatsuro Kuwahara; Teppei Okamura; Toshimi Kageyama; Yuki Kujuro
 
Oct 19, 2026
 
Prev Next